Skip to main content

Urine biomarkers for gentamicin-induced acute kidney injury in the neonatal ICU

Introduction

Gentamicin (GM) is an aminoglycoside frequently used in the neonatal ICU to treat infections. Despite low resistance and costs, GM is also nephrotoxic and may cause acute kidney injury (AKI). Serum creatinine appears to be an insensitive and unreliable marker in this setting. The objective of this study was to determine whether urine biomarkers are useful for early detection of gentamicin-induced AKI in neonates in the neonatal ICU.

Methods

Subjects

Thirty-three neonates (26 male/seven female, gestational age ± 36 weeks) with a bladder catheter without pre-existent kidney disease were divided into a GM group (n = 20) and a reference group (n = 13).

Study design and procedures

A prospective, clinical observational trial with non-invasive procedures. Demographics, vital signs and clinical conditions were recorded. Every 2 hours, during the period of bladder catheter, urine samples were collected and renal injury biomarkers glutathione-S-transferase A1-1 (GSTA1-1), GSTP1-1, kidney injury marker-1 (KIM-1), N- acetyl-β-D-glucosaminidase (NAG) and neutrophil gelatinase-associated lipocalin (NGAL) were determined. Residual blood samples were used to measure serum creatinine (sCr).

Results

Demographics were similar between both groups expect for baseline BUN (P < 0.04), which disappeared after the first day of the study. No significant differences were found in baseline kidney function, hemodynamics, ventilation support and reason for admission. Treatment with GM resulted in higher levels of sCr compared with the reference group (58.5 (44.8 to 78.5) vs. 34 (28.3 to 58.8) mmol/l; P < 0.05). The average time until the highest peak was shorter for both GSTA1-1 and GSTP1-1 compared with sCr (P < 0.05). Furthermore, higher levels of sCr corresponded with higher levels of urine biomarkers and KIM-1, NAG and GSTP1-1 could differentiate between the GM and reference group.

Conclusions

Higher sCr levels correspond with higher urinary excretion of all biomarkers, especially after GM use. In addition, the urinary biomarker GSTP1-1 might be useful for early detection of AKI in the neonatal ICU.

Author information

Affiliations

Authors

Corresponding author

Correspondence to D Jansen.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Cite this article

Jansen, D., Heemskerk, S., Koster-Kamphuis, L. et al. Urine biomarkers for gentamicin-induced acute kidney injury in the neonatal ICU. Crit Care 15, P106 (2011). https://doi.org/10.1186/cc9526

Download citation

Keywords

  • Acute Kidney Injury
  • Bladder Catheter
  • Measure Serum Creatinine
  • High Urinary Excretion
  • Baseline Kidney Function